课题基金 / 基金详情

Retroviral Transduction Core

Retroviral Transduction Core
逆转录病毒转导核心
批准号:
7896832
负责人:
WARREN S PEAR
金额:
$11.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
未结题
起止时间:
2002-09-13 至

项目摘要

项目成果

WARREN S PEAR的其他基金

相似基金

相关文献

中文摘要
翻译
该项目的许多实验方案都依赖于逆转录病毒转导原代细胞, 或培养的细胞。由于逆转录病毒制备和转导技术需要高度的生物相容性, 技术专门知识,一个执行这些技术的中央设施将大大提高 所有项目的进展。逆转录病毒制备和转导的中心设施将提供多种 集团的优势。这些措施包括:1)制备高滴度逆转录病毒的统一程序 上清液,2)高滴度逆转录病毒上清液的定期可用性,3)逆转录病毒的定期监测 上清液以确保它们不含支原体并且不含可复制的逆转录病毒, 和4)在胎儿肝脏和骨髓造血干细胞转导方面的专业知识, 研究计划的协作性质,高滴度逆转录病毒上清液和程序的可用性 对于转导,连同方案和试剂的标准化将非常有益于 节目中的每个人。逆转录病毒核心将被安置在皮尔博士的研究空间。芯会 购买和维护这些程序所需的设备。此外,消耗品也将 由核心部批量采购,以确保材料的标准化和批量采购折扣。
英文摘要
Many of the experimental protocols for the projects in this program rely on retroviral transduction of primary or cultured cells. Because the techniques of retroviral preparation and transduction require a high degree of technical expertise, a central facility where these techniques are performed would significantly enhance the progress of all projects. A central facility for retroviral preparation and transduction would offer multiple advantages to the group. These include: 1) uniform procedures for preparing high titer retroviral supernatants, 2) regular availability of high titer retroviral supernatants, 3) periodic monitoring of retroviral supernatants to insure that they are mycoplasma-free and do not contain replication competent retrovirus, and 4) expertise in transduction of fetal liver and bone marrow hematopoietic stem cells, Because of the collaborative nature of the research program, availability of high titer retroviral supernatants and procedures for transduction, together with standardization of protocols and reagents would be of great benefit to everyone in the program. The retroviral core will be housed in Dr. Pear's research space. The Core will purchase and maintain equipment necessary for these procedures. Additionally, consumables will also be purchased in bulk by the Core to ensure standardization of materials and bulk purchase discounts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
  • 批准号:
    10338110
  • 项目类别:
  • 资助金额:
    $50.25万
  • 财政年份:
    2020
  • 负责人:
    WARREN S PEAR
  • 依托单位:
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
  • 批准号:
    10548886
  • 项目类别:
  • 资助金额:
    $50.25万
  • 财政年份:
    2020
  • 负责人:
    WARREN S PEAR
  • 依托单位:
Targeting the Notch:Myc axis in leukemia/lymphoma
  • 批准号:
    10322391
  • 项目类别:
  • 资助金额:
    $44.95万
  • 财政年份:
    2018
  • 负责人:
    WARREN S PEAR
  • 依托单位:
Role of Notch signaling in the Differentiation and Function of Inflammatory DCs
  • 批准号:
    8386239
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2012
  • 负责人:
    WARREN S PEAR
  • 依托单位:
海外基金